Medtronic: A Smaller Company. A Stronger Investment? | EP027 Published: 2026-10-21T05:00:10Z Reviewed: 2026-10-21T04:54:06.821663+00:00 Codex AI production review read all 308 selected V02 transcript segments and 612 across both complete takes; verified source facts, complete framework, six video frames and 421 actual-token-timed captions. Documented acronym/proper-name/ASR display corrections preserve timing; numerical claims were not silently rewritten. The RSS enclosure is a platform transcode of the same complete approved recording: full decoded waveform correlation 0.999905, zero detected lag, and matching 1136.454-second duration. No full uninterrupted listening or perfect phonetic verification; upstream manual/source-display QA remains OPEN. Colloquial divestment terminology and moving-house/nerve-wire analogies have documented scope limits in reviewed notes. [0:00] You know, usually when a massive corporation spins off a division, the [0:03] playbook is just, well, it's pretty standard. [0:06] Right. You just sell the piece that doesn't fit and you pocket the cash. [0:08] Exactly. You pocket billions and hopefully you reinvest it somewhere smarter. [0:13] But Medtronic just did something entirely different with their diabetes business. [0:17] Oh, definitely. [0:17] Instead of selling it for cash, they basically traded the remaining stake in it [0:21] for their own shares. [0:22] It's a really fascinating move and it sets up this central mystery for us today. [0:27] Like, can a leaner, more focused medical device company actually turn growing [0:31] hospital procedure rates into real returns for investors? [0:35] That's the million dollar question. [0:37] Yeah. So welcome to this deep dive on AI Investment Edge, episode 27. [0:42] It's really the perfect test case for how modern corporate strategy actually hits the [0:45] balance sheet. [0:47] And just to set our baseline right away, the actual September released model labels [0:51] were a buy for both the one year and five year horizons. [0:55] OK, a buy for both. [0:57] Yes. But we need to be very precise here. [0:59] Those views, they are based on the original September reference price. [1:02] Right. [1:03] These are dated model assessments and they're looking out to the third quarter of [1:07] 2027 and the third quarter of 2031. [1:10] Got it. [1:11] So we aren't looking at like a fresh October rescore today. [1:14] No, exactly. [1:15] We are stress testing the underlying business fundamentals to see if that [1:19] original conditional view still holds water. [1:23] And I guess to understand if this leaner version of Medtronic works, you really have [1:27] to know what they are stripping down to, right? [1:29] Absolutely. [1:29] Because this is an absolute giant in hospital medical tech. [1:33] We are talking about life-saving hardware, pacemakers like the Micra, Evolut heart [1:38] valves, ablation catheters, and major robotic systems like Hugo. [1:43] Yeah, it is a very hardware heavy operation. [1:45] Right. [1:46] But building great hardware is really only step one. [1:49] Exactly. [1:50] I mean, the revenue model relies on selling the initial capital equipment, getting [1:54] those implants into patients. [1:56] And then, and this is key, securing that recurring revenue from disposable [2:00] instruments during repeat procedures. [2:04] But none of that happens in a vacuum. [2:06] No, it doesn't. [2:07] It depends on doctors actually adopting the tech, regulators approving it, and [2:11] insurance companies actually deciding it's worth reimbursing. [2:15] Which brings us back to the separation that completed on October 15th. [2:19] Right, the split. [2:20] Yeah, they split off the MiniMed diabetes business. [2:22] But the actual mechanics of how they did it are so crucial. [2:27] This wasn't a cash sale, right? [2:29] And it wasn't an automatic free distribution of shares to everyone holding [2:32] Medtronic stock. [2:34] No, it was an exchange. [2:35] Exactly. [2:36] Participating shareholders essentially exchanged their Medtronic parent shares for [2:40] MiniMed shares. [2:41] Right, so it's essentially like a stock buyback. [2:44] But instead of spending actual cash, Medtronic used the diabetes business as [2:48] currency to retire their own parent shares. [2:51] Which means mathematically, fewer slices of the pie should make the remaining slices [2:54] more valuable, right? [2:56] Well, on paper, yes. [2:58] That share count reduction is a clear tailwind for per-share metrics. [3:02] But the operational reality is a lot more complex. [3:06] Because of the lost revenue? [3:07] Exactly. [3:08] By shedding MiniMed, they also removed all the earnings that the diabetes business [3:12] generated. [3:14] And on top of that, breaking apart a massive corporate infrastructure like that [3:17] involves significant transition costs. [3:20] Oh, for sure. [3:21] So, the benefit of having fewer outstanding shares is immediately offset by those lost [3:25] earnings and the sheer friction of the split. [3:28] It's like downsizing from a mansion to a smaller house to save on property taxes. [3:33] But then you spend all your savings on the moving company, the real estate agent, and [3:36] all new furniture. [3:37] That's a great way to put it. [3:39] The long-term math might work out, but the upfront friction is just brutal. [3:43] So, let's look at the financial reality of this newly focused company, starting with [3:47] their top line. [3:48] Okay, let's do it. [3:50] So, if you're looking at their first quarter of fiscal year 2027, which ended [3:54] July 31st, [3:55] they reported about $9.8 billion in revenue and 13.7% organic [4:00] growth. [4:01] Right. [4:02] For a legacy hardware company, 14% growth sounds like a rocket ship, but there's a [4:06] massive asterisk there. [4:08] Oh, yeah. [4:09] The extra selling week. [4:10] Right. [4:11] They had an extra week in that quarter, which artificially pumped about $570 [4:16] million into that top line. [4:18] Yep. [4:19] It's like a retail store bragging about record weekly sales, but they were actually [4:23] open for eight days instead of seven. [4:25] It totally distorts the picture. [4:26] It really does. [4:28] And when you adjust for that and look at an ordinary week estimate, the growth is [4:31] roughly 7%. [4:32] Okay, 7%. [4:34] Now, 7% is still a very solid number for a company of this scale, but it requires a [4:38] totally different valuation mindset than a sustainable 14% run rate. [4:43] Right, because the real test is what happens when we get back to normal length [4:47] quarters. [4:48] Exactly. [4:48] And, you know, revenue is just vanity if you don't keep the cash, which takes us [4:51] right into profitability. [4:53] Looking at fiscal year 2026, their GAAP operating margin was basically flat at [4:58] 17.8%. [5:00] Right, very flat. [5:01] And in this recent Q1 of 2027, that GAAP margin ticked up just slightly to [5:05] 18.1%. [5:07] Right. [5:07] And just to translate for anyone not staring at an accounting textbook right [5:10] now, GAAP stands for generally accepted accounting principles. [5:14] It's the strict, unvarnished reality. [5:17] Exactly. [5:18] Which is distinct from the adjusted margin they like to highlight, which sits around [5:22] 24%. [5:23] But either way, maintaining those margins is an uphill battle right now. [5:27] Well, the broader environment for medical devices is just incredibly tight. [5:31] Yeah. [5:31] I mean, yes, a better mix of highly profitable procedures and a simpler [5:34] corporate structure can help expand margins. [5:37] But they are operating in a post-COVID reality where hospital procurement boards [5:41] are aggressively fighting for every single dollar. [5:45] Oh, absolutely. [5:46] And you add in tariffs and those internal transition costs we just talked about. [5:50] And that margin expansion is something they have to violently defend every single [5:54] quarter. [5:55] Right. [5:55] So if you're a listener holding this stock, you're probably looking at the balance [5:58] sheet for some comfort. [6:00] You'd hope so. [6:01] Pre-separation, at the end of July, they were sitting on about $8.8 billion in cash [6:05] and investments. [6:07] Okay. [6:07] But you have to weigh that against roughly $28 billion in combined debt. [6:11] Yeah, that's a lot of leverage. [6:12] It is. [6:13] And that leverage combined with all the intangible assets sitting on their books [6:17] from past acquisitions means their financial flexibility really has limits. [6:22] It makes the safety of their dividend conditional on them executing perfectly. [6:26] It's not an absolute guarantee. [6:28] Which is exactly why we have to scrutinize their capital allocation. [6:31] We need to see exactly where the cash is going. [6:33] Right. [6:34] So in fiscal year 2026, they spent about $1.9 billion on property and equipment [6:39] additions. [6:40] Okay. [6:41] That's roughly 5.2% of their sales. [6:43] But you know that $1.9 billion doesn't really tell us the whole story, does it? [6:47] No, it doesn't. [6:48] Because we don't have the breakdown of how much of that is just basic maintenance, [6:51] like keeping the lights on, versus actual growth spending. [6:54] Plus, research and acquisitions are entirely extra. [6:57] Oh, absolutely. [6:58] Just look at September. [6:59] They announced an investment in Cornerstone Robotics for roughly $700 million. [7:03] Yep. [7:04] And that was paid out in Q2 of fiscal 2027. [7:07] So the cash is just flowing out in multiple directions. [7:11] Let's actually trace that cash bridge. [7:13] Okay. [7:14] We can trace it clearly for fiscal year 2026. [7:17] You start with about $7.3 billion in operating cash flow. [7:21] Right. [7:21] And you subtract that $1.9 billion for the property and equipment additions. [7:25] And you arrive at a company-defined free cash flow of about $5.4 billion. [7:30] Okay. [7:30] So $5.4 billion sounds massive in a vacuum. [7:33] Sure does. [7:34] But I'm looking at their historical free cash flow. [7:36] And back in fiscal 2022, they were pulling in about $6 billion. [7:41] Right. [7:41] Then it dropped to $4.6 billion in 2023, hovered around $5.2 billion through 2024 [7:46] and 2025. [7:47] And now we are at $5.4 billion. [7:50] Yeah. [7:50] It looks less like uninterrupted compounding growth and more like they are [7:55] just slowly trying to recover lost ground. [7:58] That historical context is so vital, especially because those past figures still [8:01] include the diabetes business that they just separated. [8:05] Oh, right. [8:05] Good point. [8:06] So when we transition from this historical cash generation to projecting future [8:12] value, the market is effectively pricing in whether that recovery can accelerate [8:16] without the MiniMed division. [8:18] Let's map out what that means for the actual stock price. [8:20] Where are we setting the baseline? [8:22] We are referencing the last available Alpaca IEX trade from October 20th, which [8:26] was sitting at about $95 U.S. dollars. [8:29] Okay. [8:30] And for clarity, that's an intraday snapshot from an alternative exchange, not [8:34] a certified consolidated close. [8:37] Got it. [8:38] But using that $95 base, the evidence-weighted targets place the stock [8:43] at roughly $102 by the third quarter of 2027 and $145 [8:48] by the third quarter of 2031. [8:51] Okay. [8:51] So translating that into returns from the $95 reference, we are looking at [8:56] cumulative price gains of about 7.6% for that near horizon and 53% for the [9:02] longer one. [9:03] Correct. [9:04] And it's really worth pointing out that the first horizon is now less than a year away. [9:08] Right. [9:08] And we cannot ignore the dividend component here. [9:11] Definitely not. [9:12] The latest $0.72 quarterly dividend was paid on October 16th. [9:16] So that is already in the past. [9:18] But if we assume a flat $0.72 going forward. [9:22] Which is roughly $2.9 annually. [9:24] Exactly. [9:25] The math becomes very interesting. [9:27] Before the third quarter of 2027 horizon, there are three future payments, adding [9:32] about $2.2 in cash per share. [9:34] Okay. [9:35] And before the 2031 horizon, there are 19 payments, which adds [9:40] about $13.7 in cash. [9:42] Wow. [9:43] So if you aren't reinvesting those dividends, and we look at this expressly [9:47] before tax and fees, those gross cash-inclusive returns jumped to 9.9% for [9:52] 2027 and 67% for 2031. [9:55] Right. [9:56] Those are the base targets. [9:57] But to understand the true risk profile, we have to look at the qualitative extremes. [10:01] The best and worst case scenarios? [10:03] Exactly. [10:03] The scenarios where things go exceptionally right or horribly wrong. [10:08] Now, the numerical endpoints for these aren't locked in, but the drivers are [10:11] really clear. [10:13] Okay. [10:13] What's the bull case? [10:14] In a qualitative bull case, you would see a much faster adoption of their recurring [10:19] technologies, like the ablation catheters. [10:22] And they would manage to squeeze much better margins out of the continuing [10:25] business, easily beating those gradual assumptions. [10:28] And the bear case? [10:30] In a qualitative bear case, hospital pricing pressure, sluggish uptake of their [10:34] surgical robotics, and those lingering transition costs just completely overwhelm [10:38] the mathematical benefit of the smaller share count. [10:41] So, if you're an investor trying to figure out which way this will swing, you really [10:44] have to watch the four quadrants of their business. [10:47] Yes, absolutely. [10:49] The core drivers pushing them forward are overall procedural demand and the wider [10:52] adoption of their ablation tech. [10:54] Right. [10:55] But the core frictions pushing back are rival device platforms fighting for the [10:59] same contracts, tight hospital equipment budgets, and just the plain execution costs [11:04] of running a leaner ship. [11:06] Well, the real volatility, however, lives in the tails. [11:09] Oh, for sure. [11:10] On the upside tail, a massive catalyst would be securing additional indications [11:14] for the Hugo robotic system that actually lead to hospitals utilizing more [11:18] instruments. [11:19] Yeah. [11:20] Another major conditional upside is securing broader reimbursement for renal [11:24] denervation. [11:26] Actually, let me pause on that renal denervation thing for a second, because the [11:29] mechanism there is fascinating and easily misunderstood. [11:33] It really is. [11:33] It's a procedure designed to lower blood pressure in selected patients. [11:36] But it uses catheter delivered energy to disrupt sympathetic nerves around the renal [11:42] arteries. [11:43] Right. [11:43] Not inside the kidneys. [11:44] Exactly. [11:45] It is not destroying kidney tissue or nerves inside the kidneys. [11:49] It's like carefully cutting the communication wire on the outside of a [11:52] building to quiet a blaring alarm rather than smashing the alarm box inside the [11:56] building. [11:57] That's a really good analogy. [11:59] The safety profile is just entirely different because of that distinction. [12:02] And that distinction is critical for regulatory and clinical trust. [12:06] It highlights why regulatory approval, insurance coverage, and actual hospital use [12:10] are three completely distinct hurdles. [12:12] Right. [12:13] That upside remains conditional until all three are cleared. [12:16] Now, on the downside tail, the massive risks are pretty binary. [12:21] Like what? [12:21] A major device safety failure, a widespread recall, or a severe reimbursement [12:27] reset. [12:28] Oh, wow. [12:28] Yeah. [12:29] Even if underlying procedure volumes are growing perfectly, a statutory price shock [12:33] from insurers or governments can decimate their margins. [12:37] So, with all these moving parts, the extra selling weeks, the margin pressures, the [12:42] new technologies, where is the alpha gap? [12:45] That's the question. [12:46] If you are analyzing this, where is the broader market getting the story wrong? [12:51] Well, the internal research gap hinges on two opposing mistakes. [12:55] Okay. [12:56] The first is excessive pessimism. [12:58] Are investors wrongly waving away every strong quarter of genuine procedure growth [13:03] as just calendar noise because of anomalies like that extra selling week? [13:08] Right. [13:08] Dismissing the good news. [13:09] Exactly. [13:10] The opposing mistake is blind optimism. [13:13] Are investors paying a premium valuation for the illusion of uninterrupted growth [13:17] and effortless margin expansion, completely ignoring the reality of hospital budgets? [13:22] Yeah, that makes sense. [13:23] The investable test to solve this is measuring ordinary length growth plus cash [13:28] generation per remaining share, specifically using comparable reporting for [13:32] the continuing business. [13:34] So, how did the AI models actually process that conflict? [13:38] Because I know there's a very specific setup behind these projections. [13:41] Oh, absolutely. [13:42] The September panel is comprehensive. [13:44] It consists of 14 AI research contributions, analyzing the data across [13:48] nine framework perspectives, utilizing three distinct model versions. [13:53] Okay. [13:54] And 12 of those contributions actually share the same model release. [13:57] Wow. [13:58] And just to clarify for the listener, we are talking about disagreement among [14:02] correlated AI perspectives here, right? [14:04] Yes. [14:05] This is based on research credibility weights. [14:07] This is not like a survey of human Wall Street analysts throwing out event [14:10] probabilities. [14:12] That is exactly right. [14:13] The models that lean toward growth are favoring a pipeline-driven revaluation of [14:17] the stock. [14:18] They really see the new tech paying off. [14:20] Right. [14:20] But the more skeptical AI models are heavily emphasizing the friction, the [14:25] realities of hospital budgets, the fierce competition, and the execution risk of the [14:31] separation. [14:32] Okay. [14:33] The evidence weights aggregate the credibility of those research perspectives. [14:36] They do not assign numerical probabilities to specific events. [14:41] So as these models project forward, what are the actual windows we should be [14:45] watching? [14:46] Well, the models track scenario checkpoints through the fourth quarter of 2026 and then [14:50] the first, second, and third quarters of 2027. [14:53] Okay. [14:54] But it is vital to remember that these are model windows. [14:58] They are not scheduled, confirmed company events or guaranteed earnings dates. [15:02] Right. [15:02] Of course. [15:03] You have to watch the actual quarterly results to see the ordinary length sales, [15:08] the real margins, and the actual transition costs. [15:11] You know, it strikes me that the completion of this separation in October is a massive [15:15] fundamental change from the research batches we were looking at back in July and [15:19] September. [15:21] Oh, completely. [15:22] Back then, the focus was mostly on whether the demographic demand was resilient and [15:26] adjusting for that extra week. [15:28] Now, what was just a proposed corporate action is a completed reality. [15:33] It fundamentally changes the structure, yes. [15:35] But completing a separation does not automatically guarantee better earnings. [15:39] No, definitely not. [15:41] To really grasp what Medtronic needs to prove, it helps to revisit a few of our [15:45] previous deep dives. [15:46] Oh, good idea. [15:47] Our Boston Scientific conversation serves as the perfect benchmark for understanding [15:52] the intense competition in ablation and how those procedures actually convert into [15:57] profit. [15:58] Right. [15:58] And our Novo Nordisk conversation provides essential context on the pharmaceutical [16:02] side, demonstrating that the rise of weight loss drugs doesn't necessarily eliminate [16:06] the demand for structural medical devices. [16:09] And I'd add our Northrop Grumman conversation to that list, too. [16:12] Oh, absolutely. [16:13] That episode set the baseline for how a massive multi-year order book actually [16:17] turns into cash. [16:19] Obviously, a hospital buying a fleet of surgical robots is very different from the [16:22] government buying defense systems. [16:25] Sure. [16:25] But Medtronic faces that exact same parallel test. [16:29] Can you efficiently convert complex hardware orders into actual free cash flow? [16:34] That is the ultimate test. [16:36] Which brings us to risk management. [16:39] What invalidates this entire thesis? [16:41] Right. [16:42] What are the specific triggers that prove this conditional view wrong? [16:46] You have to reassess immediately if repeated normal length quarters show that [16:50] procedural growth is failing. [16:53] Okay. [16:53] Or if pricing pressure from hospitals starts eroding their margins despite high [16:58] procedural volume. [16:59] Or if the costs of the separation completely wipe out any per share progress. [17:04] That makes sense. [17:06] Most crucially, if free cash flow stops covering the dividend and the essential [17:10] investments in their pipeline, the thesis just breaks. [17:13] Right. [17:14] Retiring shares cannot mask underlying operational failure. [17:18] And naturally, any major product setback or safety recall warrants a fast reset of [17:23] expectations. [17:25] So let's pull all of this together. [17:27] The dated September models say buy at both the one-year and five-year horizons. [17:32] Yes. [17:33] The conditional thesis today is that a leaner, more focused Medtronic can indeed [17:38] compound cash without needing to be priced like a hyper-growth tech stock for the math [17:42] to work. [17:43] But the entire burden of proof rests on their post-separation economics and their [17:47] performance in standard, ordinary length quarters. [17:51] The structural benefits are there, but execution is everything. [17:55] That's exactly what we started with. [17:57] They traded away a piece of themselves to get leaner. [17:59] But being leaner only matters if it helps you run faster. [18:03] Exactly. [18:03] Which leaves me with one final thought for you to ponder. [18:06] If software, data, and AI become the most critical, high-margin parts of hospital [18:10] practice in the future, can a hardware-heavy legacy company like [18:14] Medtronic capture that value? [18:16] Or are they destined to just be the dependable plumbing of the medical world? [18:20] That is really the defining question for their next decade of growth. [18:24] We highly encourage you to explore the linked Medtronic consensus page to see the [18:28] exact calculations and AI weights for yourself. [18:30] And definitely go back and listen to our Boston Scientific, Novo Nordisk, and [18:34] Northrop Grumman conversations to see how all these industry threads connect. [18:38] Definitely check those out. [18:39] Be sure to follow or subscribe for our future research. [18:42] You will not want to miss our upcoming deep dive into Adyen, where we'll be posing a [18:45] really fascinating curiosity. [18:48] When global payment volumes grow exponentially, how much of that actually [18:51] becomes durable platform profit? [18:54] Thanks for joining us, and we'll catch you next time.